Numbers

Bibliography of the person, including all types of documents, not only theses.

MSc theses (1)

1. Eva Černec: Vpliv ranolazina in trimetazidina na koncentracijo katepsina S v serumu bolnikov s stabilno ishemično boleznijo srca

Other documents (13)

1. Sabina Ugovšek, Miran Šebeštjen: Lipoprotein(a)—the crossroads of atherosclerosis, atherothrombosis and inflammation
2. Andreja Rehberger Likozar, Aleš Blinc, Katarina Trebušak Podkrajšek, Miran Šebeštjen: LPA genotypes and haplotypes are associated with lipoprotein(a) levels but not arterial wall properties in stable post-coronary event patients with very high lipoprotein(a) levels
3. Andreja Rehberger Likozar, Tina Levstek, Tina Karun, Katarina Trebušak Podkrajšek, Janja Zupan, Miran Šebeštjen: Treatment with PCSK9 inhibitors influences microRNAs expression and changes of arterial wall properties
4. Patricija Lunar, Hana Meglič, Mateja Vehar, Sabina Ugovšek, Andreja Rehberger Likozar, Miran Šebeštjen, Janja Zupan: Effect of PCSK9 inhibitors on regulators of lipoprotein homeostasis, inflammation and coagulation
5. Sabina Ugovšek, Andreja Rehberger Likozar, Tina Levstek, Katarina Trebušak Podkrajšek, Janja Zupan, Slobodan Antonić, Miran Šebeštjen: Gain of function variants in PCSK9 gene in high risk patients after myocardial infarction with increased lipoprotein (a) values and treated with statins
6. Andraž Cerar, Gregor Poglajen, Gregor Zemljič, Sabina Frljak, Neža Žorž, Martina Jaklič, Renata Okrajšek, Miran Šebeštjen, Bojan Vrtovec: SGLT2 inhibitors are associated with left ventricular reverse remodeling in patients with non-compaction cardiomyopathy
7. Tine Bajec, Neža Žorž, Sabina Ugovšek, Gregor Zemljič, Andraž Cerar, Sabina Frljak, Renata Okrajšek, Petra Girandon Sušanj, Miran Šebeštjen, Bojan Vrtovec, Gregor Poglajen: Vericiguat Therapy Is Associated with Reverse Myocardial Remodeling in Chronic Heart Failure with Reduced Ejection Fraction
8. Andreja Rehberger Likozar, Sabina Ugovšek, Miran Šebeštjen: Effects of proprotein convertase subtilisin-kexin type 9 inhibitors on inflammatory and hemostatic parameters in post myocardial infarction patients
9. Sabina Ugovšek, Andreja Rehberger Likozar, Tina Levstek, Katarina Trebušak Podkrajšek, Janja Zupan, Frieda Marka, Tamara Trimmel, Mira Brekalo, Walter Speidl, Philipp Hohensinner, Patrick Haider, Miran Šebeštjen: Proprotein convertase subtilisin/kexin type 9–CC-motif chemokine ligand 2 interactions link lipoprotein(a) composition to intermediate monocyte inflammation in coronary artery disease
10. Sabina Ugovšek, Andreja Rehberger Likozar, Tina Levstek, Katarina Trebušak Podkrajšek, Janja Zupan, Frieda Marka, Tamara Trimmel, Mira Brekalo, Walter Speidl, Philipp Hohensinner, Patrick Haider, Miran Šebeštjen: PCSK9 inhibitors increase CD34+ but not other endothelial progenitor cells in patients with chronic coronary disease and increased Lp(a) values
11. Tina Levstek, Tina Karun, Andreja Rehberger Likozar, Miran Šebeštjen, Katarina Trebušak Podkrajšek: Interplay between microRNAs, serum proprotein convertase subtilisin/kexin type 9 (PCSK9), and lipid parameters in patients with very high lipoprotein(a) treated with PCSK9 inhibitors
12. Barbara Šernek, Rok Kamnikar, Miran Šebeštjen, Anja Boc, Vinko Boc: Smoking and diabetes attenuate number of CD34⁺ haematopoietic stem cells in peripheral blood of patients with advanced peripheral artery disease
13. Sabina Ugovšek, Gregor Zemljič, Andraž Cerar, Sabina Frljak, Renata Okrajšek, Miran Šebeštjen, Ivan Kneževič, Zvezdana Dolenc-Stražar, Gregor Poglajen: Case report